ScreenPoint Medical Acquires Biomediq to Boost Breast Cancer Risk Assessment

ScreenPoint Medical has acquired Biomediq A/S, a company specialized in quantitative imaging biomarkers, to enhance their capabilities in breast cancer risk assessment using their leading product, Transpara. This deal solidifies nearly a decade of collaboration between the two companies, aiming to improve early breast cancer detection by integrating Biomediq's mammographic texture analysis with Transpara’s lesion detection and density tools. The acquisition is expected to enable more advanced screening techniques that could double the early detection rate of breast cancer while reducing recall rates. Andreas D. Lauritzen, PhD, will join ScreenPoint Medical to further enhance Transpara's development. Max Nielson from Biomediq will serve as an ongoing advisor, emphasizing the harmonious collaboration in advancing mammography-based risk assessment. ScreenPoint Medical is globally recognized for its AI technology that supports radiologists through advanced imaging techniques for early cancer detection.